Graybill 2024: RARE DISEASE DRUG DEVELOPMENT
HOSTED BY COLORADO STATE UNIVERSITY IN FORT COLLINS, CO
JUNE 9 – 12, 2024
We are very pleased to announce a four-day conference Graybill 2024: Rare Disease Drug Development, on June 9-12, 2024, hosted by Colorado State University. The 2024 Graybill Conference will be held jointly with the 2024 WNAR/IMS Annual Meeting.
The conference will offer 4 short courses covering topics unique to rare disease drug development, including
- N-of-1 Trials for personalized healthcare. Christopher Schmid, Brown University.
- Small Sample Sequential Multiple Assignment Randomized Trial (SNSMART) designs and methods for chronic rare disease drug development. Kelley Kidwell, University of Michigan.
- The Door is Open: a patient-centric pragmatic approach to clinical trials based on benefit-risk. Scott Evans and Toshimitsu Hamasaki, George Washington University.
- Bayesian borrowing techniques for rare disease clinical research. Joseph Koopmeiners and Steffen Ventz, University of Minnesota.
The conference will feature a keynote talk by Dr. Scott Evans (George Washington University) and keynote regulatory panel consisting of Dr Gregory Levin (FDA), Dr. Guei-Feng (Cindy) Tsai (Taiwan CDE), Dr. Andrew Thompson (EMA) and Dr. Frank Pitavy (EMA). The conference will also feature 8 invited sessions that cover all aspects on challenges and opportunities in rare diseases drug development. Additionally, the conference offers a career lunch roundtable to students and young professionals who are interested in drug development.
It's not often you find such a concentration of experts in one location focusing on rare disease research, and another reason to register today for the conference.
Please visit https://statistics.colostate.edu/graybill-conference-2024/ for more details and register today.
------------------------------
Jingjing Ye
Executive Director
BeiGene
------------------------------